HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hain on organic developments

This article was originally published in The Rose Sheet

Executive Summary

Hain Celestial says it supports the National Organic Standards Board's recommendation (by 12 to 1 vote) for the U.S. Department of Agriculture to police the organic personal-care sector as it does the food industry, with respect to standards established under the National Organic Program. In a Nov. 12 release, Hain states: "A few natural product competitors and their supporters have attempted to misrepresent the NOSB recommendation in an unfortunate effort to unfairly disparage our brands." The Organic Consumers Association celebrated NOSB's Nov. 5 recommendation as a victory against brands perpetrating "organic cosmetics fraud," the same brands targeted by the group's recently launched boycott, which includes Hain's Jason and Avalon Organics lines. "Hain Celestial will continue to work with industry participants and government agencies to draft and formalize standards surrounding the use of the term 'organic' in personal-care products. Until such standards are established, it is up to all of us in the industry to work together to self-regulate for label integrity and consumer clarity," says Hain, a founding member of the OASIS coalition (1"The Rose Sheet" Aug. 10, 2009)

You may also be interested in...



OASIS Upholds Value Of Private Organic Standards, Points To Food History

The Organic And Sustainable Industry Standards association maintains that litigation and quibbling over certification criteria are counterproductive, in that ultimately it is the consumer who loses out

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel